Phathom Pharmaceuticals (PHAT) Short term Debt (2020 - 2021)
Phathom Pharmaceuticals (PHAT) posted quarterly Short term Debt of $10.3 million for Q2 2021, up 644.78% year-over-year from $1.4 million in Q2 2020, and down 12.07% quarter-over-quarter from $11.8 million in Q1 2021.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Short term Debt (2020 - 2021) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Short term Debt for 2 consecutive years, with $10.3 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Short term Debt rose 644.78% year-over-year to $10.3 million; the TTM figure through Jun 2021 stood at $10.3 million (up 644.78% YoY), while the FY2020 annual figure was $7.4 million, changed N/A from the prior year.
- Short term Debt eased to $10.3 million in Q2 2021 per PHAT's latest filing, from $11.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $11.8 million in Q1 2021 and bottomed at $1.4 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 10.35 Mn |
| Mar 31, 2021 | 11.77 Mn |
| Dec 31, 2020 | 7.35 Mn |
| Sep 30, 2020 | 5.56 Mn |
| Jun 30, 2020 | 1.39 Mn |